Bristol And Pfizer Team Up To Develop Anticoagulant Apixaban In $1 Billion Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
In a separate agreement, the firms will also collaborate on the development of Pfizer’s preclinical metabolic disorder compounds.